Department of Gastroenterology, University Hospital of Rennes, Pontchaillou, France.
INSERM U1241, University of Rennes 1, Rennes, France.
Inflamm Bowel Dis. 2018 Jun 8;24(7):1612-1618. doi: 10.1093/ibd/izy055.
BACKGROUND & AIMS: The European Crohn's and Colitis Organization recommends magnetic resonance imaging (MRI) of anal fistulas to decide on the drug/surgery strategy. No evidence is available on the long-term impact of MRI features on fistula healing. The aim of this study was to evaluate the benefit of combined drug/surgery strategies for the treatment of perianal Crohn's fistulas based on MRI factors at referral.
The clinical event (anal abscess, new fistula tract, cellulitis), therapeutic intervention (introduction/optimization of immunosuppressant/biologics, anal surgery, intestinal resection, stoma), and MRI data were prospectively recorded for patients with Crohn's disease (CD) and anal fistulas. Healing was defined by fulfilment of all the following conditions: no discharge or pain, closure of the external opening of the fistula, no visible internal opening, no abscess, and no subsequent draining seton or drainage procedure performed during at least 1 year of follow-up.
Seventy CD patients with anal fistulas and MRI evaluations were followed for 70 months. The cumulative rates of fistula healing were 25%, 40%, 50%, and 70% at 12, 24, 36, and 72 months, respectively. Severe, complex, branched, and high fistulas were associated with a less favorable outcome. Surgical closure of the tract improved the healing rates better than treatment with biologics or thiopurines. Male sex, A1 luminal phenotype, and anal ulceration at referral were independently associated with a higher healing rate.
Therapeutic strategies for perianal fistulizing CD require robust anatomical and healing evaluations. Combined strategies using biologics to improve both drainage and secondary closure of the fistula tracts merit further study.
欧洲克罗恩病和结肠炎组织建议对肛门瘘管进行磁共振成像(MRI)检查,以决定药物/手术策略。目前尚无 MRI 特征对瘘管愈合的长期影响的证据。本研究旨在评估基于转诊时的 MRI 因素,对肛周克罗恩病瘘管采用联合药物/手术策略治疗的效果。
前瞻性记录克罗恩病(CD)伴肛门瘘管患者的临床事件(肛门脓肿、新瘘管、蜂窝织炎)、治疗干预(免疫抑制剂/生物制剂的引入/优化、肛门手术、肠道切除术、造口术)和 MRI 数据。愈合定义为满足以下所有条件:无分泌物或疼痛、瘘管外口闭合、无可见内口、无脓肿、且在至少 1 年的随访期间无后续引流挂线或引流操作。
70 例 CD 伴肛门瘘管和 MRI 评估的患者接受了 70 个月的随访。12、24、36 和 72 个月时,瘘管愈合的累积率分别为 25%、40%、50%和 70%。严重、复杂、分支和高位瘘管与预后较差相关。与生物制剂或硫嘌呤治疗相比,手术闭合瘘管可提高愈合率。男性、腔表型 A1 和初诊时的肛门溃疡与更高的愈合率独立相关。
肛周瘘管型 CD 的治疗策略需要进行强有力的解剖和愈合评估。联合使用生物制剂改善引流和瘘管的二次闭合的治疗策略值得进一步研究。